MyoWorks Gains Mastercraft Backing for Smart Therapy Tools

A patient’s discomfort interrupted the treatment that would become MyoWorks’ founding idea. The company describes a clinician adding electrical stimulation during a painful soft-tissue session, an adjustment that eventually led to a tool made in a small Wisconsin machine shop. That practical intervention now sits behind a business connecting treatment instruments with clinical software.

MyoWorks announced an investment from Mastercraft Ventures on November 10, 2026. The Windsor, Wisconsin startup builds for chiropractors, physical therapists and other musculoskeletal care providers. The investment amount was undisclosed; WisBusiness identified the financing as pre-seed in its reporting based on an interview with Mastercraft managing director Mason Cook.

Founder Dr. Jeremy Quick brings more than a decade of chiropractic experience to the effort. The capital supports software and connected treatment-system development, with the company working toward market introduction. Its commercial proposition connects two activities a practice already performs: delivering hands-on care and maintaining a useful account of that care.

From a treatment-room adjustment to a connected instrument

MyoWorks’ official company history places a patient encounter before the software architecture. Electrical stimulation helped make a difficult treatment more tolerable, according to the company, and the early hardware took shape at a machine shop in Lodi. Software engineer Joe Scanlin subsequently helped connect the instrument to a platform for recording treatment and organizing clinical information.

That sequence helps explain the company’s design priorities. A clinician wants the instrument to work naturally in the hand while capturing information that can be used after the session. Software usefulness depends partly on what the physical tool can measure during treatment, giving hardware ergonomics and documentation a shared commercial purpose.

The instrument lineup includes MyoOne, an instrument-assisted soft-tissue tool; MyoOne E, which adds electrotherapy; and MyoTrio, which combines treatment modalities. MyoWorks describes a common clinical record across the family. The products are listed as coming soon, and the site invites practices to request early access.

The early-access language belongs inside any assessment of the investment. MyoWorks is asking other practitioners to consider an approach developed from clinical experience while the business continues building its offering. A device that suits its inventor’s treatment room still has to find a comfortable place in another clinician’s working day, alongside that person’s patients, preferences and existing routines.

The clinical record becomes part of the product

MyoWorks describes instruments that capture treatment time by body region, stroke cycles, cadence and blade angle. Its software uses treatment information and patient outcomes to draft SOAP notes, the Subjective, Objective, Assessment and Plan record used in clinical practice. The clinician can review, edit and sign the draft, retaining responsibility for the finished account.

On its platform description, MyoWorks emphasizes linking statements in the note to underlying measurements, treatments or plans. That is a specific answer to a practical concern about generated documentation: a useful draft should give its author a way to inspect where its statements came from. For a practice evaluating the system, the relationship between the measurement and the sentence may matter as much as the time spent typing it.

The company also describes tracking patient progress across visits and presenting information in reports patients can understand. Those capabilities are product claims; the public announcement supplies no independent clinical study demonstrating that the system improves outcomes. The website labels its displayed software screens as synthetic demo data, so those images should be read as illustrations of the intended experience.

The operating opportunity is still concrete. Capturing information during treatment could reduce the amount a clinician must reconstruct afterward, while a shared record could support conversations about progress over several visits. Both benefits depend on the information being useful enough to review and on the instrument fitting the appointment rather than adding another task to it.

Why Mastercraft’s early-stage approach fits

Mastercraft Ventures focuses on Wisconsin founders seeking their first institutional capital, including businesses at the prototype stage. Its website names Mason Cook as founder and managing director and describes an investment approach centered on insight developed through experience. MyoWorks gives that approach a clinical example: a practitioner identifying a problem in the work and building equipment around it.

WisBusiness’ interview with Cook describes MyoWorks moving from prototype development toward market introduction. The reporting adds useful context around the financing without establishing a deal size. Mastercraft’s typical check figures describe its investing practice and cannot be substituted for the amount committed to MyoWorks.

For an investor, connecting instruments and records creates several related development assignments. The device must capture relevant information, the software must organize it coherently, and a clinician must find the resulting record worth using. Progress in one part can create new requirements in another: a richer treatment stream gives the documentation software more to interpret and the practitioner more to evaluate.

This is also where the founder’s experience becomes commercially valuable and commercially limited. Dr. Jeremy Quick knows the treatment setting from inside the work. Expanding the business asks the team to translate that knowledge into a system another practitioner can adopt, with enough consistency to support clinical review across different appointments and practices.

Introducing MyoWorks to the next clinic

The immediate audience is the musculoskeletal practice considering early access. MyoWorks is offering a connected approach to treatment capture and documentation, and its public site gives interested clinicians a route to contact the company. Pricing, a firm launch date and a verified customer count remain outside the disclosed investment story.

The record also leaves clinical effectiveness and broad practice economics for further evidence. Those questions should develop alongside deployment rather than disappear beneath the appeal of a connected instrument. A clinic evaluating the product will bring its own expectations about documentation quality, patient communication and the time available during an appointment.

For DevCuration’s healthcare-technology coverage, MyoWorks illustrates how AI development can begin with the creation of useful source data. The instrument’s place in the treatment session determines part of what the software can know. That connection gives the company’s hardware choices consequences well beyond the shape of the tool.

Dr. Jeremy Quick and Joe Scanlin are now carrying that connection toward other treatment rooms with Mastercraft’s backing. Another clinician will hold the instrument, review what the software recorded and decide how to describe the patient’s care. The business will develop through those ordinary encounters, where a founder’s design becomes somebody else’s working equipment.